Latest Cetuximab Stories
-- LUME-COLON 1 will evaluate the efficacy and safety of nintedanib in specific patients with metastatic colorectal cancer (mCRC) whose disease has progressed on previous treatment
BONN, Germany, September 29, 2014 /PRNewswire/ -- Newly published European Society for Medical Oncology (ESMO) clinical guidelines for the treatment of metastatic colorectal
-- Ramucirumab Plus FOLFIRI Improved Survival in Metastatic Colorectal Cancer following Progression on a Bevacizumab-Based Regimen -- INDIANAPOLIS, Sept.
AUSTIN, Texas, Sept.
Introduction of Extended RAS Testing and Recent Clinical Trial Data Will Affect How Physicians Treat Colorectal Cancer Patients, According to Findings from Decision Resources Group BURLINGTON,
AUSTIN, Texas, Aug.
Scientists at the inter-university Messerli Research Institute of the Vetmeduni Vienna, the Medical University of Vienna, and the University of Vienna have developed, for the first time, antibodies to treat cancer in dogs.
The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies.
For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival.
LONDON, June 26, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
- The act of burning, scorching, or heating to dryness; the state or being thus heated or dried.
- In medicine, cauterization.